Ikarian Capital LLC Increases Stock Position in uniQure (NASDAQ:QURE)

Ikarian Capital LLC raised its holdings in uniQure (NASDAQ:QURE) by 198.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 469,133 shares of the biotechnology company’s stock after purchasing an additional 311,768 shares during the period. Ikarian Capital LLC owned 0.97% of uniQure worth $2,439,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Raymond James & Associates lifted its holdings in shares of uniQure by 6.4% in the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of uniQure by 58.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 3,664 shares in the last quarter. Pale Fire Capital SE lifted its holdings in shares of uniQure by 9.2% in the fourth quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 5,500 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $86,000. Finally, SG Americas Securities LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $116,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on QURE shares. Mizuho reduced their price objective on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, July 16th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.50.

uniQure Trading Down 2.3 %

Shares of uniQure stock traded down $0.18 during trading hours on Thursday, hitting $7.48. The company’s stock had a trading volume of 1,308,728 shares, compared to its average volume of 1,764,171. The business has a fifty day moving average of $5.97 and a 200 day moving average of $5.53. The company has a market capitalization of $363.15 million, a PE ratio of -1.20 and a beta of 0.97. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). The firm had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. As a group, equities analysts forecast that uniQure will post -4.4 EPS for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.